Development of a Series of Tanshinone Derivatives Through Scaffold Hopping for Treating Non-Small-Cell Lung Cancer (NSCLC)
Molecules · 2026
DOI: 10.3390/molecules31030446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Lan-Xin Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Provincial Key Laboratory of Inno…. Hauptthemen laut MEDLINE: Abietanes, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science and Technology Department of Guizhou Province, the National Natural Science Foundation, Science and Technology Department of Guizhou Province.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) is one of the most prevalent cancer types and accounts for the majority of cancer-related deaths worldwide. Tanshinone and its derivatives exhibit diverse biological activities, and their prominent antitumor potential has been well documented. In this study, we rationally designed a series of tanshinone derivatives with a scaffold-hopping strategy. Thirty-five tanshinone derivatives were synthesized, and their cytotoxic activities against the NSCLC cell lines A549 and H838 were investigated. Concurrently, their safety profile was assessed in BEAS-2B cells. The results showed that compounds S2-1, S2-4, and S2-8 exhibited superior inhibitory activity against A549 cells compared with the positive control, β-lapachone. Meanwhile, compounds S2-1, S2-3, S2-4, S2-8, S2-13, and S2-14 exhibited similar or increased antiproliferation activity against H838 cells. Compounds S2-4 (0.58 ± 0.07 μM) and S2-8 (0.42 ± 0.04 μM) demonstrated the greatest potency towards H838 cells; compounds S2-13 (1.28 ± 0.13 μM) and S2-14 (1.80 ± 0.24 μM) exhibited potent and selective activity towards H838 cells. Molecular docking studies of S2-4/NLRP3 and S2-14/STAT3, combined with the structure–activity relationship (SAR) analysis, indicated that the benzofuran core containing an ortho-quinone, along with an amide linkage and a 1,2,3-triazole group introduced at the C-2 position of the furan ring, is an effective chemical scaffold for enhancing the anti-NSCLC activity of tanshinone derivatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, Guizhou Medical Universi…
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
- Key Laboratory for Cancer Prevention and Treatment of Guizhou Province, Guiyang 550004, China.
Förderung
- the Science and Technology Department of Guizhou Province
- the National Natural Science Foundation
- Science and Technology Department of Guizhou Province
Zitieren
APA
Zhou, L. X., Shu, Z. Y., Li, H., Zhong, H., Xu, D. N., Tang, L., Hu, C. J., Luo, C., & Xiong, H. (2026). Development of a Series of Tanshinone Derivatives Through Scaffold Hopping for Treating Non-Small-Cell Lung Cancer (NSCLC). Molecules. https://doi.org/10.3390/molecules31030446
Vancouver
Zhou LX, Shu ZY, Li H, Zhong H, Xu DN, Tang L, et al. Development of a Series of Tanshinone Derivatives Through Scaffold Hopping for Treating Non-Small-Cell Lung Cancer (NSCLC). Molecules. 2026. doi:10.3390/molecules31030446
BibTeX
@article{Zhou2026,
author = {Zhou, Lan-Xin and Shu, Zheng-Yu and Li, Heng and Zhong, Hui and Xu, Dou-Nan and Tang, Lei and Hu, Chu-Jiao and Luo, Cheng and Xiong, Huan},
title = {Development of a Series of Tanshinone Derivatives Through Scaffold Hopping for Treating Non-Small-Cell Lung Cancer (NSCLC)},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31030446}
}
EUVIMED